Stealth BioTherapeutics to Present at JMP Life Sciences Conference

NEEDHAM, Mass., May 6, 2024 -- Stealth Biotherapeutics Inc. (Stealth), a biotechnology company at the clinical-stage dedicated to the discovery, development, and commercialization of innovative treatments for diseases associated with mitochondrial dysfunction, announced that its CEO, Reenie McCarthy, will engage in a fireside chat at the JMP Citizens Life Sciences Conference in New York. This event is scheduled for Monday, May 13, at 2:30 p.m. ET, where McCarthy will also conduct one-on-one meetings with investors.

A live webcast of McCarthy's presentation will be accessible online, and a replay will be available for a limited period following the event.

Stealth Biotherapeutics is at the forefront of developing therapies for mitochondrial dysfunction-related diseases, both age-related and rare genetic conditions. The company's leading investigational product, elamipretide, is set to begin Phase 3 clinical trials for the treatment of dry age-related macular degeneration. This condition is a significant cause of vision loss in older adults. Additionally, elamipretide is being evaluated in a Phase 3 clinical trial for primary mitochondrial myopathy, a debilitating skeletal muscle disease. The U.S. Food and Drug Administration is also reviewing elamipretide for Barth syndrome, a very rare condition that affects both the heart and skeletal muscles.

Moreover, Stealth is advancing its second-generation candidate, bevemipretide (SBT-272), which is currently in clinical stages for addressing both ophthalmic and neurological diseases. The company boasts a robust pipeline of mitochondrial-targeted compounds that are being explored as potential therapeutic candidates.

Stealth Biotherapeutics is deeply invested in addressing the underlying causes of mitochondrial dysfunction through its innovative research and development efforts. The company's focus on both common and ultra-rare diseases underscores its commitment to bringing novel treatments to market, offering new hope for patients with limited options.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!